Shorter regimens for tuberculosis
Bedaquiline, pretomanid and other shorter TB regimens.
Key point
For adolescents aged 14 years and above and adults with MDR/RR-TB, 6-month BPaLM is recommended over 9-month or longer regimens.
From: [Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)] (Zhonghua Jie He He Hu Xi Za Zhi, 2026 Jun 12) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 12, 11, 8, 11, 10.
New guidelines and consensus this year
- Tuberculosis research principles and priorities in children and adolescents: an international consensus statementLancet Child Adolesc Health2026 Aug
- [Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)]Zhonghua Jie He He Hu Xi Za Zhi2026 Jun 12
All papers from the last 12 months
358 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Pyrazinamide-derived 1,2,3-triazoles: Antimicrobial evaluation, selective antimycobacterial activity and mechanism of action insightsEur J Med Chem2026 Nov 5PMID 42341628
- Drug-resistance profiles, population structure, genomic clustering, and temporal trends in drug resistance among Mycobacterium tuberculosis complex isolates in Ukraine, 2019-2023: a multicentre cohort studyLancet Reg Health Eur2026 NovPMID 42761426
- Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach MethodologyClin Pharmacol Ther2026 NovPMID 42638221
- Effectiveness and Safety of Contemporary Drug Regimens for Multidrug- and Extensively Drug-resistant Tuberculosis in Children and Adolescents: A Global Systematic Review and Meta-analysisPediatr Infect Dis J2026 Nov 1PMID 42162945Meta-analysisSystematic review
- Altered physiology of drug-resistant Mycobacterium tuberculosis restricts adaptation to host-relevant conditions and produces condition-dependent collateral vulnerabilitiesmBio2026 Oct 14PMID 42782108
- Availability of genotypic and phenotypic drug susceptibility testing for Mycobacterium tuberculosis in WHO European RegionIJTLD Open2026 OctPMID 42866176
- Dual targeting of cytochrome bd and bc(1)-aa(3) terminal oxidases eradicates phenotypically diverse population of Mycobacterium tuberculosisBiomed Pharmacother2026 Oct 12PMID 42863244
- Targeting Latent Tuberculosis Using Hypoxia-Activated Prodrugs of Bedaquiline AnaloguesACS Med Chem Lett2026 Oct 8PMID 42866428
- Design, Synthesis, and Antimicrobial Activity of Novel Cyt-bd Inhibitors Targeting Energy Compensation in Mycobacterium tuberculosisACS Med Chem Lett2026 Oct 8PMID 42865993
- Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South AfricaPLoS One2026PMID 42848774
More infectious diseases trends
All specialties →Metagenomic sequencing diagnostics
Metagenomic next-generation sequencing to identify pathogens.
RSV vaccines in older adults
RSV vaccination for adults aged 60 and older.
New antibiotics for resistant Gram-negatives
Cefiderocol, sulbactam-durlobactam and other new agents.
H5N1 avian influenza
H5N1 bird flu in animals and humans.
Dengue
Dengue spread, vaccines and treatment.
Mpox
Mpox epidemiology, vaccination and treatment.
Key point: Paediatric mpox shows variable PCR positivity, progressive skin lesions and fever, with younger children more susceptible to severe complications.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
tuberculosis[tiab] AND (bedaquiline[tiab] OR pretomanid[tiab] OR BPaL[tiab] OR BPaLM[tiab] OR "shorter regimen*"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.